StockData
Elanco Animal Health Inc logo

Elanco Animal Health Inc (ELAN) stock

ELANNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 9/30148% above fair value
$26.70+0.85 (+3.29%)

Close on Nov 18, 2026Market cap $13.34BP/E –Yield –

Earnings

Elanco Animal Health's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 23, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$1.27B
+11.3% on a year earlier
Adjusted EPS, Q3 FY2026
$0.27
$0.19 a year earlier
Latest guidance
Issued
Nov 6, 2026 · 7 items

Quarterly results

Revenue and earnings per share from each of Elanco Animal Health's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Feb 23, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Nov 6, 2026before the open$1.27B+11.3%$0.04$0.27Release
Q2 FY2026ended Jun 30, 2026Aug 5, 2026before the open$1.37B+10.2%$0.11$0.34Release
Q1 FY2026ended Mar 31, 2026May 6, 2026before the open$1.37B+14.9%$0.11$0.40Release
Q4 FY2025ended Dec 31, 2025Feb 24, 2026before the open$1.14B+12.2%-$0.56$0.13Release
Q3 FY2025ended Sep 30, 2025Nov 5, 2025before the open$1.14B+10.4%-$0.07$0.19Release
Q2 FY2025ended Jun 30, 2025Aug 7, 2025before the open$1.24B+4.8%$0.02$0.26Release
Q1 FY2025ended Mar 31, 2025May 7, 2025before the open$1.19B-1.0%$0.13$0.37Release
Q4 FY2024ended Dec 31, 2024Feb 25, 2025before the open$1.02B-1.4%-$0.02$0.14Release
Q3 FY2024ended Sep 30, 2024Nov 7, 2024before the open$1.03B-3.6%$0.73$0.13Release
Q2 FY2024ended Jun 30, 2024Aug 8, 2024before the open$1.18B+12.0%-$0.10$0.30Release
Q1 FY2024ended Mar 31, 2024May 8, 2024before the open$1.21B-4.1%$0.06$0.34Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Elanco Animal Health's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Revenuenon-GAAPQ4 FY2026$1.19B – $1.22B–NewNov 6, 2026
Adjusted EBITDAnon-GAAPQ4 FY2026$185.00M – $200.00M–NewNov 6, 2026
Adjusted Earnings per Sharenon-GAAPQ4 FY2026$0.16 – $0.19–NewNov 6, 2026
organic constant currency growthnon-GAAPFY2026+6% – +7%–NewAug 5, 2026
organic constant currency revenue growthFY2026+5% – +7%–NewMay 6, 2026
RevenueFY2026$5.09B – $5.14B$5.01B – $5.09BRaisedAug 5, 2026
revenue guidancenon-GAAPFY2026$5.16B – $5.18B–NewNov 6, 2026
adjusted gross marginnon-GAAPFY202655.8% – 56%–NewNov 6, 2026
adjusted gross marginnon-GAAPFY202655.2% – 55.6%55.1% – 55.5%RaisedAug 5, 2026
Adjusted EBITDAnon-GAAPFY2026$1.05B – $1.07B–NewNov 6, 2026
Adjusted EBITDAnon-GAAPFY2026$1.01B – $1.04B$975.00M – $1.01BRaisedAug 5, 2026
Adjusted EPSnon-GAAPFY2026$1.17 – $1.20–NewNov 6, 2026
Adjusted EPSnon-GAAPFY2026$1.10 – $1.16$1.03 – $1.09RaisedAug 5, 2026
innovation revenuenon-GAAPFY2026$1.20B–NewMay 6, 2026
innovation revenue targetnon-GAAPFY2026$1.25B–RaisedAug 5, 2026
year-end net leverage ratio targetnon-GAAPFY202633 – 3.2LoweredAug 5, 2026

Guidance vs results

The last range Elanco Animal Health gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
Q3 FY2026Adjusted Earnings per Share$0.19 – $0.22$0.27Above range
Q3 FY2026Revenue$1.20B – $1.22B$1.27BAbove range
Q3 FY2026Revenue growth+5% – +7%+11.26%Above range
Q2 FY2026Adjusted Earnings per Share$0.25 – $0.28$0.34Above range
Q2 FY2026Revenue$1.30B – $1.33B$1.37BAbove range
Q1 FY2026Adjusted Earnings per Share$0.33 – $0.36$0.40Above range
Q1 FY2026Revenue$1.28B – $1.31B$1.37BAbove range
FY2025Adjusted EPS$0.91 – $0.94$0.95Σ4QAbove range
FY2025EPS (GAAP)-$0.11 – -$0.08-$0.48Σ4QBelow range
FY2025Revenue$4.65B – $4.67B$4.72BΣ4QAbove range
Q4 FY2025Adjusted Earnings per Share$0.09 – $0.12$0.13Above range
Q4 FY2025EPS (GAAP)-$0.20 – -$0.17-$0.56Below range

Guidance history

Every forecast Elanco Animal Health put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 6, 2026Adjusted EBITDAFY2026$1.05B – $1.07BNew
Nov 6, 2026Adjusted EBITDAQ4 FY2026$185.00M – $200.00MNew
Nov 6, 2026Adjusted Earnings per ShareQ4 FY2026$0.16 – $0.19New
Nov 6, 2026Adjusted EPSFY2026$1.17 – $1.20New
Nov 6, 2026adjusted gross marginFY202655.8% – 56%New
Nov 6, 2026revenue guidanceFY2026$5.16B – $5.18BNew
Nov 6, 2026RevenueQ4 FY2026$1.19B – $1.22BNew
Aug 5, 2026Adjusted EBITDAQ3 FY2026$200.00M – $215.00MNew
Aug 5, 2026Adjusted EBITDAFY2026$1.01B – $1.04BRaised
Aug 5, 2026Adjusted EPSFY2026$1.10 – $1.16Raised
Aug 5, 2026Adjusted Earnings per ShareQ3 FY2026$0.19 – $0.22New
Aug 5, 2026adjusted gross marginFY202655.2% – 55.6%Raised
Aug 5, 2026operating expensesQ3 FY2026+10%New
Aug 5, 2026year-end net leverage ratio targetFY20263Lowered
Aug 5, 2026innovation revenue targetFY2026$1.25BRaised
Aug 5, 2026revenue growthQ3 FY2026+5% – +7%New
Aug 5, 2026RevenueQ3 FY2026$1.20B – $1.22BNew
Aug 5, 2026organic constant currency growthFY2026+6% – +7%New
Aug 5, 2026RevenueFY2026$5.09B – $5.14BRaised
May 6, 2026Adjusted EBITDAQ2 FY2026$240.00M – $260.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Elanco Animal Health filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Results
  4. Results
  5. Update
  6. Update
  7. Results
  8. Results
  9. Update
  10. Results
  11. Update
  12. Results
  13. Update
  14. Update
  15. Results

See a number that looks wrong?